Screener
Discontinued — last reported Q4 '25
CapEx at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 5:02 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-012399
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 | Year ended December 31, 2023 |
|---|---|---|---|
| Purchases of short-term investments | (348,669) | (268,313) | (354,918) |
| Maturities of short-term investments | 252,469 | 260,640 | 354,967 |
| Acquisition of IPR&D assets | (40,000) | (40,500) | (5,667) |
| Purchases of property and equipment | (953) | — | (47) |
| Net cash used in investing activities | (137,153) | (48,173) | (5,665) |
| Financing activities | |||
| Repayment of deferred royalty obligation | (19,917) | (12,900) | (7,398) |
| Proceeds from issuance of common stock upon completion of public offering, net of offering costs | 188,657 | — | — |
Item 16. Form 10-K Summary
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s capex?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported capex of $238.25K in Q4 2025.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s capex?
- Over 3 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s capex has grown at a 30.0% compound annual growth rate (CAGR), from $434K to $953K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude